Clinical trials: Pharmacogenetic Testing, open to volunteers
Pharmacogenetic Testing
Pharmacogenetic Testing at Community Pharmacy
The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription.
- Trial name
- OffiGene (NCT06210321)
- Testing
- Prescription of escitalopram using pharmacogenetic testing
- Volunteers
- 270 people
- Sponsor
- Chantal Csajka
Hypercholesterolemia
Pharmacogenomic Informed Statin Prescribing
Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins.
- Trial name
- NCT06568601
- Testing
- Pharmacogenetic and polygenic risk testing, Active control
- Where
- 2 sites in United States
- Volunteers
- 214 people
- Sponsor
- VA Office of Research and Development
Adverse Drug Reaction, Therapy Failure
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care.
- Trial name
- NCT04154553
- Testing
- Buccal swab, EDTA Blood sample (4.9mL), Serum sample (7.5mL)
- Where
- Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Pediatric Cancer
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets.
- Trial name
- NCT06744712
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wake Forest University Health Sciences
Mental Health, Depressive Disorder
Assessing the Impact of the Personalized Medicine Clinic on Mental Health Outcomes
The aim of this study is to investigate if personalized dosing of antidepressant medications using information gathered at the Personalized Medicine Clinic can improve patients' mental health.
- Conditions
- Mental Health, Depressive Disorder, Pharmacogenetic Testing, Antidepressant
- Trial name
- NCT07601477
- Testing
- Personalized Medicine Clinic
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pharmacogenetics, Depression - Major Depressive Disorder
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment…
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Trial name
- COMPASS-PGx (NCT07373470)
- Testing
- Comprehensive medication management with PGx testing results, Usual Care
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Pittsburgh
All Malignancies, Children Being Treated for Catastrophic Illness
Pharmacogenetic Determinants Of Treatment Response In Children
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates.
- Trial name
- NCT00730678
- Where
- United States
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
CDK4/6 Inhibitor, Breast Cancer
Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors
The goal of this research study is to reduce adverse effects of anti-cancer medications known as kinase inhibitors, while preserving their therapeutic benefits. There have been major advances in the way cancers are treated.
- Conditions
- CDK4/6 Inhibitor, Breast Cancer, CYP3A4 Protein, Human, Drug Interaction
- Trial name
- NCT07100054
- Testing
- Whole gene sequencing, Drug-drug interaction analysis, Biomarker analysis
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of…
- Trial name
- PGx (NCT06335043)
- Testing
- Pharmacogenetics Testing
- Where
- Canada
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Polypharmacy, Pharmacogenetics
Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.
- Conditions
- Polypharmacy, Pharmacogenetics, Pharmacogenomic Testing, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT05247814
- Testing
- Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism, Adverse Drug Reaction detection, Falls Efficacy Scale International (FES-I)
- Volunteers
- 2,000 people
- Sponsor
- RWTH Aachen University
Adverse Drug Reaction (ADR)
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.
- Trial name
- NCT04249375
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Fall, Fall Accident
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications.
- Conditions
- Fall, Fall Accident, Poly Pharmacy, Adverse Drug Events
- Trial name
- GREAT PHARM (NCT07216846)
- Testing
- DNA care pathway
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Florida Atlantic University
Pharmacogenomic Testing for Medication Management
Reduction of Adverse Drug Events and Readmissions
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
- Trial name
- RADAR-PGX (NCT02738047)
- Where
- United States
- Volunteers
- 280,000 people, healthy volunteers welcome
- Sponsor
- ClinLogic LLC
Patients Undergoing Routine Health Care, Heart Diseases
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance…
- Conditions
- Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease
- Trial name
- NCT01280825
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Depression
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy
In this study at the Solothurn Psychiatric Clinic, the investigators compare the effectiveness and tolerability of antidepressant pharmacotherapy in three groups.
- Trial name
- PrePGx (NCT04507555)
- Testing
- Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing, Standard care antidepressant selection and dosing
- Where
- 4 sites in Switzerland
- Volunteers
- 190 people
- Sponsor
- PD Dr. med. Thorsten Mikoteit
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan